Home » Topics » Regulatory » EMA

EMA
RSS

Abbott withdraws European MAA for Ozespa

Jan. 19, 2011

ChemGenex notifies EMA of withdrawal of MAA for Tekinex for Ph+ CML

Jan. 17, 2011

New indication for Lucentis in E.U. for vision loss in diabetic macular edema

Jan. 11, 2011

EMA and FDA grant expedited review for boceprevir

Jan. 11, 2011

Invega approved in E.U. for schizoaffective disorder

Jan. 7, 2011

EMA to review Allos' MAA for Folotyn in relapsed or refractory PTCL

Dec. 28, 2010

Novartis receives E.U. approval for Tasigna in newly diagnosed Ph+ CML

Dec. 27, 2010

CHMP recommends marketing authorization for Janssen-Cilag's Xeplion

Dec. 23, 2010

CHMP recommends a variation to marketing terms for Simponi

Dec. 23, 2010

CHMP recommends approval of Teysuno for treatment of advanced gastric cancer

Dec. 23, 2010

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 24, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 24, 2025.
Researchers discover how glioblastoma tumors dodge chemotherapy
BioWorld MedTech
Researchers at the University of Sydney have uncovered a mechanism that may explain why glioblastoma returns after treatment, and the world-first discovery offers...
Apollo’s APL-4098 shows potent antileukemic effects
BioWorld Science
Apollo Therapeutics Ltd. has developed APL-4098, a small-molecule general control nonderepressible 2 (GCN2) inhibitor for the potential treatment of AML.
HIV research is close to a cure but far from ending the pandemic
BioWorld
Advances in antiretroviral therapy (ART) now allow people living with HIV to lead normal lives with undetectable and nontransmissible levels of the virus in their...